Drug Trial Radar · NCT06197568
Proof of Concept Study of Vaginal AZU-101 in Vulvovaginal Atrophy in Postmenopausal Women
Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Jul 1, 2026
Primary completion
Dec 31, 2026
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Azure Biotech Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Nucleus Network Ltd
- First posted
- Jan 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 45 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study Objectives: Primary: • To assess the safety, tolerability, and systemic pharmacokinetics (PK) of AZU-101 Secondary: • To evaluate efficacy of daily vaginal doses of AZU-101 in postmenopausal women on vaginal epithelium
Conditions
- Vulvo Vaginal Atrophy (VVA)
Interventions
Lasofoxifene TartrateDrug
1.0 ug for 14 daily doses
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Had Any Serious Adverse Events or Any Treatment Emergent Adverse Events With Severity Greater Than "Moderate" as measured by CTCAE v4.0Time frame: 15 days
- Pharmacokinetics (AUC0-∞)Time frame: 24 hours after day 1 and day 14
- Pharmacokinetics (Tmax)Time frame: 24 hours after day 1 and day 14
- Pharmacokinetics (Cmax)Time frame: 24 hours after day 1 and day 14
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nucleus Network
Saint Paul, Minnesota · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.